Citigroup Initiates Coverage On Alkermes with Neutral Rating, Announces Price Target of $22
Citigroup analyst Navann Ty initiates coverage on Alkermes (NASDAQ:ALKS) with a Neutral rating and announces Price Target of $22.
75 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) surged 436.7% to settle at $48.30 on Tuesday after the company priced its IPO at $9 per share.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
SVB Leerink Maintains Market Perform on Alkermes, Lowers Price Target to $24
SVB Leerink analyst Marc Goodman maintains Alkermes (NASDAQ:ALKS) with a Market Perform and lowers the price target from $27 to $24.
Alkermes Announces Receipt Of Notices Of Partial Termination From Janssen Pharmaceutica In Respect Of Two License Agreements; Says ‘The terminations impact know-how royalties related to sales of long-acting paliperidone products’
Alkermes plc (NASDAQ:ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a
Why Are Alkermes Shares Trading Lower Today?
Alkermes plc (NASDAQ:ALKS) posted Q3 sales of $294.1 million, up 11% Y/Y, missing the consensus of $301.36 million. Vivitrol sales…
Alkermes Q3 EPS $0.14 Beats $0.06 Estimate, Sales $294.14M Miss $301.36M Estimate
Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.06 by 133.33 percent. This is a 46.15 percent decrease over earnings of $0.26 per share from the same
Earnings Scheduled For October 27, 2021
Companies Reporting Before The Bell
• McDonald's (NYSE:MCD) is expected to report quarterly earnings at $2.46 per share on revenue of $6.03 billion.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
Alkermes Announces Commercial Availability of LYBALVI For The Treatment Of Schizophrenia And Bipolar I Disorder
Alkermes plc (NASDAQ:ALKS) today announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States (U.S.) for the treatment of adults with schizophrenia, and